1. Medtech Insight
  2. >>Business
  3. >>Startups & SMEs

Start-Up Spotlight: Arkis BioSciences, Endexo-Boosted Ventricular Drainage Catheter Reduces Obstructions

 
• By Bob Kronemyer

Arkis BioSciences Inc.'s newly launched CerebroFlo EVD catheter for treating intracranial hypertension offers an added benefit of being impregnated with Endexo, an antiocclusive agent that in laboratory studies has shown to dramatically reduce the incidence of thrombus formation, which can potentially reduce catheter obstructions.

Start-up Spotlight

Unlike traditional catheters that drain cerebrospinal fluid from the brain to relieve pressure when treating intracranial hypertension in an intensive care unit (ICU) setting, the CerebroFlo external ventricular drainage (EVD) catheter from Arkis BioSciences Inc. has the added benefit of being impregnated with Endexo (developed by Canadian-based Interface Biologics Inc.), an antiocculsive agent previously commercialized for vascular access catheters.

Arkis BioSciences Inc.

1 Momentum Way

Knoxville, TN 37920

Phone: (844) 247-5383

Web Site: www.arkisbiosciences.com

Contact: Chad Seaver, CEO

Industry Segment: Neurosurgical

Business: Minimally invasive surgical instrumentation and next-generation...

“Endexo is not a drug-eluting catheter, which is an advantage,” Arkis CEO Chad Seaver told Medtech Insight. “Endexo is a polymer additive. It is not a coating that depletes over...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Startups & SMEs

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

LSX Europe: Women’s Health Education Is The Key For Unlocking VC Investment

 
• By Natasha Barrow

Flo Health was the first femtech unicorn to be valued at over $1bn. But the company faced 49 investment rejections before reaching that status, Anna Klepchukova, the company’s chief medical officer, told the LSX World Congress Europe. THENA Capital’s Esther Reynal de St Michel Richardot talked through the firm’s gender-smart investment strategy.

‘Pathologists Are Hungry For AI-Enabled Digital Pathology’

 
• By Natasha Barrow

Digital pathology makes it possible to unlock insights previously hidden to the human eye, “reshaping how we diagnose and treat patients,” said Nathan Buchbinder, co-founder and chief strategy officer at Proscia. He shared his views on the future of digital pathology and the lessons he has learned from working with pathologists.

LSX Roundup: Startups Elypta, QuantiLight And Plexaa Debut New Tech

 
• By Natasha Barrow

Back-to-back meetings at LSX? No time to attend the innovator showcase? Here is what you might have missed from medtech innovators at the LSX World Congress Europe on 29 April.

More from Business

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.